intuit procedur growth impress bewar
updat forecast estim jul
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
intuit surgic develop produc market robot system
assist minim invas surgeri also provid instrument
dispos accessori warranti servic system compani
place roughli da vinci system hospit world-wide
instal unit state grow number emerg
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
decad explos growth becom
victim success tougher comp challeng
key procedur slow trajectori given
moder dvp dvh question surround robot
cost return invest still expect total
number procedur tripl next decad
answer ceil virtual unlimit exist
applic robot surgeri scratch surfac
possibl procedur could migrat robot next
other cardiothorac still offer sizeabl unpenetr
under-penetrated opportun outsid unit
state western europ face similar constraint
 robot surgeri penetr europ significantli
lower includ significantli under-penetrated market
japan robot surgeri still ampl room grow
absenc formid competitor intuit surgic
continu domin robot surgeri arena even
cost-consci environ europ adopt
robot surgeri remain robust
believ growth start deceler number
procedur penetr rate hit ceil area
dvp also believ compani increasingli run
manual laparoscopi viabl altern need
continu suppli practition tangibl evid benefit
robot surgeri clinic well econom front
focu cost control coupl rather
well-satur field compani increasingli reli growth
intern seen sceptic past
said believ intuit competit posit remain superb
system sale like never reach growth rate
past compani still healthi growth profil driven mainli
expect continu double-digit growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intuit procedur growth impress bewar
rich valuat jul
intuit procedur growth continu defi
expect surpris strong
uptak robotic-assist surgeri gener surgeri
matur procedur remain elev level midway
year intuit procedur growth sit
well forecast compani guidanc
rais forecast procedur full
year lead boost fair valu estim
per share maintain wide
second-quart procedur growth driven
growth outsid consid
total volum da vinci growth
noth short remark uptak gener surgeri
surpris hernia colorect adopt rate
larg line forecast unexpect
strength matur procedur buoy volum
approxim year year expect
dvh dvp remain elev compani
see trend sustain
instrument accessori revenu grew last year
note substanti percentag
total unit sale volum attribut trade-in
third quarter row trade-in
third total unit placement bit surpris
consid xi famili around sever year
anticip level moder system sale
pull back comparison particularli
firm margin earn growth line
expect anticip margin pressur
latter part year new sp model roll-out
compani trade time sale
nearli time earn well histor high
remain bearish compani share
valuat growth profit jul
rais fair valu estim per share
account much stronger-than-anticip
procedur growth forecast system sale
instrument servic revenu directli tie
procedur volum forecast top two procedur dvp
dvh slow significantli peak rate
penetr rate robot surgeri radic prostatectomi
alreadi high japan dvp growth
driven market size increas thu new market
china crucial growth
deceler overal hysterectomi market
like continu per year on-going
pressur hospit use manual mi possibl
coupl chang percept toward benign
hysterectomi like caus dvh struggl
expand penetr rate beyond current level
project benign dvh volum remain
essenti flat throughout long-term forecast
posit view intuit opportun
gener surgeri colorect hernia procedur
quickli becom second-largest cohort
compani expect gener surgeri market
grow nearli next three year overal
procedur growth rate averag high singl digit
throughout forecast
expect growth rate system revenu becom
much less attract opinion vast major
instal platform easili absorb addit procedur
util rate go averag sell price
pressur forecast system sale low
singl digit instrument servic revenu expect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
margin grow minim compani maintain
price structur face competit fair valu
estim jump per share forecast
consid scenario highli unlik
downsid could see downward pressur dvp
acceler dvh lose share laparoscopi
procedur fail make much ground procedur compound-annual-growth-rate
stay around system revenu declin part
owe competit pressur instrument servic
revenu rise midsingl digit margin also
pressur valuat drop per share
given wide rang outcom believ high
uncertainti rate appropri
expand instal base roughli da
vinci system vast procedur databas think
intuit surgic dug wide moat around busi
system instrument price reflect firm
monopoli statu nich allow
achiev profit rare enjoy medic equip
maker adjust oper margin
fact gross margin intuit system compar
instrument consum compon profit
distinct industri consum
rare attract rapidli grow market
robot surgeri stay impenetr competit
long firm monopoli sooner later
ceas exist sever emerg competitor
none potenti significantli disrupt firm
oper erod return capit intuit
intellectu properti
system grow
instrument base sizeabl barrier
ever-grow clinic databas present biggest
challeng new entrant amass bodi data
grow rapidli midsingl high singl digit
per year line procedur growth forecast
expect margin exceed impli
double-digit growth oper incom period
margin expans trajectori slower
intuit abl deliv recent believ
sever factor slow expans futur
mix toward lower-pr procedur roll-out sp
platform carri lower margin eventu pressur
competit
virtual upsid limit valuat
compani fate tie size procedur market
abl penetr marketplac
hundr million procedur main reason
firm almost alway command lofti valuat
multipl bull case expect firm total
procedur volum grow million would
boost system revenu compound-annual-growth-rate instrument
servic respect overal
revenu growth forecast oper
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becom
unchalleng robot surgeri field
increasingli run manual surgeri particularli
ventur outsid core surgic area even
struggl take share manual lap
convert open procedur robot lack
evid clinic benefit particularli benign surgeri
instead reli cosmesi eas use sell dvh
increasingli tougher sell
cash-strap hospit particularli addit
reimburs lack switch cost anoth
robot high hospit custom term money
train surgeon switch manual lap done
significantli less effort given surgeon familiar
mi forecast procedur overal convert
robot surgeri next decad around
procedur compound-annual-growth-rate firm profit per procedur
come sever reason fewer
satur lower averag sell price dispos
compet manual lap platform share
special challeng procedur sell cycl
intuit research develop product also
declin fewer procedur opportun emerg
innov cycl -- low-hang fruit
pick compani invest heavili order
penetr variou surgic special outsid
core urology/gynaecolog market final see
nois competit front threat
firm moat might make certain procedur
suscept price pressur
intuit possess new competitor still
year away european approv
convinc enough hospit purchas trial
instrument extens period train robot-na
da vinci-train surgeon recruit will patient
howev certain compet instrument --
price attract -- may make inroad procedures/speci
current under-penetrated intuit particularli
hospit balk da vinci cost
cost becom exorbit averag system price
around million repres larg portion typic
would need compel technolog price differ
switch machin wear natur
upgrad cycl around five eight year given need
purchas new instrument procedur instal
system provid rel depend stream
revenu per procedur long surgeon continu use
biggest threat intuit moat futur robot
surgeri gener plausibl cash-strap
hospit receiv addit reimburs robot
usag may opt plod yet cheaper altern
manual laparoscopi particularli clinic bodi work
support robot surgeri tradit mi lack
also plausibl robot surgeri may face applic
limit consid number variou
procedur alreadi perform da vinci seem
moat trend stabl stage game intuit
surgic meaning direct competitor
extend definit competit includ manual
laparoscopi intuit abil expand competit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth da vinci system assist multipl type
hospit drive procedur
intuit surgic potenti specialis rival
on-going high-margin instrument sale servic
revenu provid clinic case histori
sought surgeon hospit administr
ointuit surgic direct rival grow
base user build career
profici da vinci
owe may see emerg
competit particularli lower-cost procedur
oth firm averag utilis rate well
instal challeng hospit tri
maxim exist da vinci util
orobot gynaecolog slow probabl
continu declin forese futur along
hysterectomi gener owe gener
overus procedur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
intuit balanc sheet spotless zero debt
ampl cash compani could arguabl leverag
balanc sheet strict cash deploy polici limit
usag tuck-in acquisit reinvest share
buyback compani resum buy-back polici recent
could acceler need balanc sheet health
concern extrem limit
one key long-term risk
competitor introduc compel altern da vinci
procedur siphon intuit growth
opportun potenti reduc profit
busi also concern recent emerg regard
surgic train profici hospit low
procedur volum well number incid use
da vinci robot result pend food
drug administr probe explicitli
project liabil neg outcom trend
system could damag firm reput caus
hospit question purchas new system
use instal system litig may also result
financi hit although explicitli forecast
model final robot surgeri yet establish
good altern manual laparoscopi certain
procedur benign hysterectomi well gener
surgeri reimburs distinguish
manual robot mi robot instrument cost
hospit forc eat differ
two procedur clinic benefit well
establish manual laparoscopi may prevail seen
evid slow penetr rate benign
dvh declin growth cholecystectomi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intuit surgic superb record come
organ growth return capit technolog
revolutionari testament intuit
vision manag team abil drive
adopt expand area
superb applaud compani dedic
shield robust return capit avers expans
unrel area via acquisit appropri
share-buyback polici result rais
stewardship rate exemplari
repres date owner name posit common share held report holder issuer
new york mellon corp
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
intuit procedur growth impress bewar
rich valuat jul
intuit procedur growth continu defi
expect surpris strong
uptak robotic-assist surgeri gener surgeri
matur procedur remain elev level midway
year intuit procedur growth sit
well forecast compani guidanc
rais forecast procedur full
year lead boost fair valu estim
per share maintain wide
second-quart procedur growth driven
growth outsid consid
total volum da vinci growth
noth short remark uptak gener surgeri
surpris hernia colorect adopt rate
larg line forecast unexpect
strength matur procedur buoy volum
approxim year year expect
dvh dvp remain elev compani
see trend sustain
instrument accessori revenu grew last year
note substanti percentag
total unit sale volum attribut trade-in
third quarter row trade-in
third total unit placement bit surpris
consid xi famili around sever year
anticip level moder system sale
pull back comparison particularli
firm margin earn growth line
expect anticip margin pressur
latter part year new sp model roll-out
compani trade time sale
nearli time earn well histor high
remain bearish compani share
intuit surgic first-quart result came strong
impress growth compar first quarter
driven primarili gener surgeri
world-wide urolog maintain wide econom
moat rate fair valu estim
first-quart procedur growth driven growth
 growth market outsid
 procedur develop specialti close
follow prior-year pattern hernia repair remain main
procedur gener surgeri segment gynaecolog
show modest growth led hysterectomi urolog
procedur driven prostatectomi volum
adopt lobectomi thorac procedur
persist outsid procedur growth driven
tradit procedur dvp also early-stag growth
kidney gener surgeri gynaecolog china modest
procedur growth quarter partial affect
chines system quota negoti quota
part finalis five-year budget plan current
negoti provinc hospit japan
prostatectomi partial nephrectomi procedur growth
moder given alreadi high adopt level
instrument accessori revenu grew last year
primarili due advanc instrument usag custom
buy pattern weaker dollar system
affect higher system placement revenu deferr
million first-quart weak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
note
roll-out da vinci continu extrem
success total placement quarter
placement fourth quarter last year still
platform placement
predominantli go facil platform
outsid larg go replac
trade-in rather greenfield instal
strong procedur growth gener surgeri help
 placement worri market
approach oversatur platform end
installed-bas growth two year
itq gross margin came
post first-quart mainli due product mix
oper expens increas rel first-quart
consist intuit spend plan intuit
invest da vinci sp catheter-bas robot imag
advanc instrument expans intern
intuit finish strong note great busi
expens stock jan
intuit fourth-quart result slightli
forecast revenu bottom line
plan adjust fair valu estim reflect
out-performance cash flow realis sinc last
updat quarter cap strong year compani
total revenu grow fastest clip sinc
howev current market valuat intuit share
impli multipl seen sinc earli
decad remain impress intuit growth
market posit believ wide moat
virtual impenetr concern share
incorpor growth expect hard fulfil
procedur growth reacceler fourth quarter
full-year growth slightli
forecast surpris signific
improv matur procedur appear
buoy macroeconom trend tend lift
elect procedur hernia colorect remain main
sourc strength gener surgeri
becom largest product categori expect
growth moder next year although growth
forecast appear conserv rel recent trend
compani guidanc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
